Catalog No.
YVV33301
Expression system
E. coli
Species
Hepacivirus hominis
Protein length
Phe10-Val172
Predicted molecular weight
20.25 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
A0A0S2CFQ4
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
NS5A
Inhibition of hepatitis C virus replication in HepG2 cells via modulation of the Raf-1 and interferon-alpha signaling pathways by thymoquinone., PMID:40317342
Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants., PMID:40272375
Deciphering Host-Virus Interactions and Advancing Therapeutics for Chronic Viral Infection., PMID:40143318
The Genotypes/Subtypes and Antiviral Drug Resistance of the Hepatitis C Virus from Patients in a Tertiary Care Hospital in Nepal., PMID:40143305
A key role for hepatitis C virus NS5A serine 225 phosphorylation revealed by super-resolution microscopy., PMID:40113977
Adaptation of single molecule real time (SMRT) sequence technology for hepatitis C virus genome sequencing and identification of resistance-associated substitutions., PMID:40043634
Genotyping and treatment issues with 'unusual' HCV 1 subtypes., PMID:40011316
Hepatitis C Virus Resistance-Associated Substitutions in Mexico., PMID:40006924
In silico analysis of the effect of HCV genotype-specific polymorphisms in Core, NS3, NS5A, and NS5B proteins on T-cell epitope processing and presentation., PMID:39881992
Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries., PMID:39848793
Resistance-Associated Substitution Testing Trends and Impact on HCV Treatment Outcomes in Canada: A CanHepC-CANUHC Analysis., PMID:39785104
Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice., PMID:39772165
Hepatitis C Virus NS5A Activates Mitophagy Through Cargo Receptor and Phagophore Formation., PMID:39770398
Computational design of potent dimeric phenylthiazole NS5A inhibitors for hepatitis C virus., PMID:39738127
Development and implementation of a novel method for detecting hepatitis C virus resistance-associated substitutions to NS3, NS5A, and NS5B inhibitors in Linzhou, China., PMID:39694419
Functional Role of Hepatitis C Virus NS5A in the Regulation of Autophagy., PMID:39599533
Epitope-based therapeutic targets in HCV genotype 1 non-structural proteins: a novel strategy to combat emerging drug resistance., PMID:39575309
Roseoside Is a Bioactive Compound in Kirengeshoma koreana Nakai Extract with Potent In Vitro Antiviral Activity Against Hepatitis C Virus., PMID:39519772
Inhibitory peptides derived from Hepatitis C virus NS5A for reducing clinical symptoms of dengue virus infection., PMID:39389166
Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations., PMID:39225750
An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences., PMID:39204274
From viruses to cancer: exploring the role of the hepatitis C virus NS3 protein in carcinogenesis., PMID:39192306
Hepatitis C virus subtype distribution and resistance-associated substitutions in high-risk population groups in Guangdong Province, China., PMID:39111345
Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors., PMID:39013947
HCV 5-Methylcytosine Enhances Viral RNA Replication through Interaction with m5C Reader YBX1., PMID:38954741
Hepatitis C virus NS5A and core protein induce fibrosis-related genes regulation on Huh7 cells through activation of LX2 cells., PMID:38852781
Association between hepatitis C virus genotype 4 and renal cell carcinoma: Molecular and virological studies., PMID:38616711
Efficient Estimates of Surface Diffusion Parameters for Spatio-Temporally Resolved Virus Replication Dynamics., PMID:38474240
NOTCH localizes to mitochondria through the TBC1D15-FIS1 interaction and is stabilized via blockade of E3 ligase and CDK8 recruitment to reprogram tumor-initiating cells., PMID:38409448
CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma., PMID:38363156
Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase., PMID:38265202
Molecular-genetic pathways of hepatitis C virus regulation of the expression of cellular factors PREB and PLA2G4C, which play an important role in virus replication., PMID:38213698
Ser38-His93-Asn91 triad confers resistance of JFH1 HCV NS5A-Y93H variant to NS5A inhibitors., PMID:38116713
Ser235 phosphorylation of hepatitis C virus NS5A is required for NS5A dimerization and drug resistance., PMID:38072190
Reconstruction of the regulatory hypermethylation network controlling hepatocellular carcinoma development during hepatitis C viral infection., PMID:37978846
The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity., PMID:37896876
Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections., PMID:37835845
ASPP2 binds to hepatitis C virus NS5A protein via an SH3 domain/PxxP motif-mediated interaction and potentiates infection., PMID:37750869
Sofosbuvir plus glecaprevir/pibrentasvir as salvage therapy after liver transplantation in NS5A inhibitor-experienced patients. A case series., PMID:37699225
Mutational analysis reveals a novel role for hepatitis C virus NS5A domain I in cyclophilin-dependent genome replication., PMID:37672027
Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer., PMID:37648284
Sub-stoichiometric Modulation of Viral Targets-Potent Antiviral Agents That Exploit Target Vulnerability., PMID:37583823
Molecular characterization of patients with chronic hepatitis C virus infection in Jordan: implications on response to direct-acting antiviral therapy., PMID:37567550
Hepatitis C virus non-structural proteins modulate cellular kinases for increased cytoplasmic abundance of host factor HuR and facilitate viral replication., PMID:37540723
Identification of an Oligostilbene, Vaticanol B, from Dryobalanops aromatica Leaves as an Antiviral Compound against the Hepatitis C Virus., PMID:37532559
Hepatitis C Virus Down-Regulates the Expression of Ribonucleotide Reductases to Promote Its Replication., PMID:37513740
Endosomal egress and intercellular transmission of hepatic ApoE-containing lipoproteins and its exploitation by the hepatitis C virus., PMID:37506130
[Analysis of resistance-associated substitutions in hepatitis C virus sequences from Kyrgyzstan]., PMID:37436417
Human Mesenchymal Stem Cells Modified with the NS5A Gene of Hepatitis C Virus Induce a Cellular Immune Response Exceeding the Response to DNA Immunization with This Gene., PMID:37372076
Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa., PMID:37231989
For research use only. Not for human or drug use.
